Список литературы

1. Козлова А.Л., Мамзерова Е.С., Новичкова Г.А., Щербина А.Ю. Клинические проявления и терапия криопирин-ассоциированных периодических синдромов. Вопросы гематологии/онкологии и иммунопатологии в педиатрии, 2014; 13: 42 - 48.

2. Fietta P. Autoinflammatory diseases: the hereditary periodic fever syndromes. Acta Biomed. 2004; 75(2): 92 - 99.

3. Gattorno M. Данные конгресса PRES2018 (Pediatric Rheumatology European Society), 5 - 8 September 2018.

4. Ярилин А.А. Иммунология. - М.: ГЭОТАР-Медиа, 2010.

5. Хаитов Р.М. Иммунология: структура и функции иммунной системы: учеб. пособие/Р.М. Хаитов. - М.: ГОЭТАР-Медиа, 2014. - 280 с.

6. Kato H, Oh SW, Fujita T. RIG-I-Like Receptors and Type I Interferonopathies. J Interferon Cytokine Res. 2017 May; 37(5): 207 - 213.

7. Хаитов Р.М. Иммунология: атлас/Р.М. Хаитов, А.А. Ярилин, Б.В. Пинегин. - М.: ГОЭТАР-Медиа, 2011. - 324 с.

8. Zevini A, Olagnier D, Hiscott1 J. Cross-Talk between the Cytoplasmic RIG-I and STING Sensing Pathways // Trends Immunol. 2017 Mar; 38(3): 194 - 205.

9. Miner JJ, Diamond MS. MDA5 and autoimmune disease // Nat Genet. 2014 May; 46(5): 418 - 419.

10. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1 // Am J Med Genet A. 2015; 2015; 167A: 296 - 312.

11. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A et al. Mutations in the gene encoding the 3_-5_ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 2006; 38: 917 - 920.

12. Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, Demple B, Perrino FW, Lieberman J. The exonuclease TREX1 is in the SET complex and actsin concert with Nm23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell. 2006; 23: 133 - 142.

13. Yang YG, Lindahl T, Barnes DE. TREX1 exonuclease degrades ssDNA to prevent chronic checkpointactivation and autoimmune disease. Cell. 2007; 131: 873 - 886.

14. Stetson DB, Ko JS, Heidmann T, Medzhitov R. TREX1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008; 134: 587 - 598.

15. Reijns MA, Rabe B, Rigby RE, Mill P, Astell KR, Lettice LA, Boyle S, Leitch A, Keighren M, Kilanowski F, Devenney PS, Sexton D, Grimes G, Holt IJ, Hill RE, Taylor MS, Lawson KA, Dorin JR, Jackson AP. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell. 2012; 149: 1008 - 1022.

16. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAM HD1 as regulator of the innate immune response. Nat. Genet. 2009; 41: 829 - 832.

17. Kretschmer S, Wolf C, Konig N, Staroske W, Guck J et al. SAMHD1 prevents autoimmunity by maintaining genome stability. Ann. Rheum. Dis. 2014; 74(3): e17.

18. Liddicoat BJ, Piskol R, Chalk AM, Ramaswami G, Higuchi M, Hartner JC, Li JB, Seeburg PH, Walkley CR. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science. 2015; 349(6252): 1115 - 1120.

19. Rice GI, Del Toro DY, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet. 2014; 46: 503 - 509.

20. The American Journal of Human Genetics 96, 266 - 274, February 5, 2015 267 Mutations in DDX58, which Encodes RIG-I, Cause Atypical Singleton-Merten Syndrome Mi-Ae Jang, 1, 16 Eun Kyoung Kim, 2, 16 Hesung Now, 3 Nhung T.H. Nguyen, 3 Woo-Jong Kim, 3 Joo-Yeon Yoo, 3 Jinhyuk Lee, 4, 5 Yun-Mi Jeong, 6.

21. Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, Zhao T, Laughrea M, Wainberg MA, Hiscott J (Feb 2011). "RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I". Journal of Virology. 85 (3): 1224-36.

22. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ (Aug 2011). "MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response". Cell. 146 (3): 448-61.

23. Федоров Е.С. Протеасомные болезни - новый раздел аутовоспалительной патологии. Современная ревматология. 2013; (4): 38 - 46.

24. Amelia McDermott 1, MA, Jennifer Jacks 2, MD, Marcus Kessler 3, MD, Peter D. Emanuel 4, MD, and Ling Gao 5, MD, PhD Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management.

25. Kim H, Sanchez GA 2, Goldbach-Mansky R Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct; 94(10): 1111 - 1127. Epub 2016 Sep 27.

26. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017 Dec; 49: 96 - 102. doi: 10.1016/j.coi.2017.09.003.

27. Stefano Volpi, Paolo Picco, Roberta Caorsi, Fabio Candotti and Marco Gattorno. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J. 2016 Jun 4; 14(1): 35. doi: 10.1186/s12969-016-0094-4.

28. Torrelo A. CANDLE Syndrome As a Paradigm of Proteasome-Related Autoinflammation. Front. Immunol. 8: 927. doi: 10.3389/fimmu.2017.00927

29. Torrelo A, Patel S, Colmenero I, Gurbindo D, Lendinez F, Hernandez A, Lopez-Robledillo JC, Dadban A, Requena L, Paller AS. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J. Am. Acad. Dermatol. 2010; 62: 489 - 495.

30. Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc. Natl. Acad. Sci. USA. 2011; 108: 14914 - 14919.

31. Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, Toyoshima Y et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy inhumans. J. Clin. Invest. 2011; 121: 4150 - 4160.

32. Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, Kim PW, Sheikh A, Lee CC et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheumatism. 2012; 64: 895 - 907.

33. Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L, Aikawa NE, Jesus AA, Silva CA. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature - a rare case with a novel mutation. Eur. J. Pediatr. 2016; 175: 735 - 740.

34. Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, Montealegre G, Biancotto A et al. Additive loss-of-function proteasome subunit mutationsin CANDLE/PRAAS patients promote type I IFN production. J. Clin. Invest. 2015; 125: 4196 - 4211.

35. Brehm, A., Liu, Y., Sheikh, A., Marrero, B., Omoyinmi, E., Zhou, Q., Montealegre, G., Biancotto, A., Reinhardt, A., Almeida de Jesus, A., Pelletier, M., Tsai, W.L., and 31 others. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J. Clin. Invest. 125: 4196 - 4211, 2015. Note: Erratum: J. Clin. Invest. 126: 795 only, 2016.

36. Poli, M.C., Ebstein, F., Nicholas, S.K., de Guzman, M.M., Forbes, L.R., Chinn, I.K., Mace, E.M., Vogel, T.P., Carisey, A.F., Benavides, F., Coban-Akdemir, Z.H., Gibbs, R.A., and 16 others. Heterozygous truncating variants in POMP escape nonsense-mediated decay and cause a unique immune dysregulatory syndrome. Am. J. Hum. Genet. 102: 1126 - 1142, 2018.

37. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014; 371: 507 - 518.

38. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, Goudin N, Fremond ML, Nitschke P, Molina TJ, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014; 124: 5516 - 5520.

39. Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, Klein N, Brogan PA. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheumatol. 2015; 67: 808.

40. Munoz J, Rodiere M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, Rozenberg F, Crow YJ, Bessis D. Stimulator of interferon genes-associated vasculopathy with onset in infancy: a mimic of childhood Granulomatosis with Polyangiitis. JAMA Dermatol. 2015; 151: 872 - 877.

41. Chia J, Eroglu FK, Ozen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, Goldbach-Mansky R, Cowen EW. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016; 74: 186 - 189.

42. Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013; 14: 19 - 26.

43. Keating SE, Baran M, Bowie AG. Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol. 2011; 32: 574 - 581.

44. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014; 371: 507 - 518.

45. Briggs TA, Rice GI, Daly S, Urquhart J et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 2011; 43: 127 - 131.

46. Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat. Genet. 2011; 43: 132 - 137.

47. Lee-Kirsch MA. The type I interferonopathies. Ann. Rev. Med. 2017; 68.

48. Bogunovic D, Byun M, Durfee LA, Abhyankar A et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science. 2012; 337: 1684 - 1688.

49. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V et al. Human intracellular ISG15 prevents interferon-a/b over-amplification and auto-inflammation. Nature. 2015; 517 (7532): 89 - 93.

50. Meuwissen MEC, Schot R, Buta S, Oudesluijs G, Tinschert S et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J. Exp. Med. 2016; 213: 1163 - 1174.

51. Anja Basters, Klaus-Peter Knobeloch, USP18 - a multifunctional component in the interferon response. Bioscience Reports Nov 16, 2018.

52. Fabre A, Charroux B, Martinez-Vinson C, et al. SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. Am J Hum Genet 2012; 90: 689-92.

53. Fabre A, Martinez-Vinson C, Goulet O, et al. Syndromic diarrhea/Tricho-hepato-enteric syndrome. Orphanet J Rare Dis 2013; 8: 5.

54. Eckard SC, Rice GI, Fabre A, et al. The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat Immunol 2014; 15: 839-45.

55. https://www.orpha.net.

56. Bienias M, Griep C, Wolf C, Kretschmer S, Kind B, Berner R, Lee-Kirsch MA. Therapeutic Approaches to Type I Interferonopathies. Curr Rheumatol Rep. 2018 Apr 20; 20(6): 32.

57. Davidson S, Steiner A, Harapas CR, Masters SL. An Update on Autoinflammatory Diseases: Interferonopathies. Curr Rheumatol Rep. 2018 May 30; 20(7): 38.

58. Kato H, Oh SW, Fujita T. RIG-I-Like Receptors and Type I Interferonopathies. J Interferon Cytokine Res. 2017 May; 37(5): 207 - 213.

59. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017 Dec; 49: 96 - 102.

60. Eleftheriou D, Brogan PA. Genetic interferonopathies: An overview. Best Pract Res Clin Rheumatol. 2017 Aug; 31(4): 441 - 459.

61. Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct; 94(10): 1111 - 1127.

62. Torrelo A, Patel S, Colmenero I, Gurbindo D, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol (2010) 62: 489-95.

63. Khamashta M, Merrill JT, Werth VP, Furie P, et al. Sifalimumab, an monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study // Ann Rheum Dis. 2016 Nov; 75(11): 1909 - 1916.

64. Rice G, Forte GMA, Szynkiewicz M, Chase DS et al. Assessment of interferon-related biomarkers in syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and ADAR: a case-control study // Lancet Neurol. 2013 Dec; 12(12): 1159 - 1169.

65. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197(6): 711-23.

66. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003; 100(5): 2610-5.

67. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007; 13(1 - 2): 59 - 68.

68. Rice G, Patrick T, Parmar R, Taylor CF et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome // Am J Hum Genet. 2007b; 81: 713-25.

69. Брюханова Н.О., Жилина С.С., Айвазян С.О., Ананьева Т.В., Беленикин М.С., Кожанова Т.В., Мещерякова Т.И., Зинченко Р.А., Мутовин Г.Р., Заваденко Н.Н. Синдром Айкарди-Гутьерес у детей с идиопатической эпилепсией. Российский вестник перинатологии и педиатрии. 2016; 61(2): 68 - 75.

70. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, Goudin N, Fremond ML, Nitschke P, Molina TJ, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014; 124: 5516 - 5520.

71. Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, Klein N, Brogan PA. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheumatol. 2015; 67: 808.

72. Munoz J, Rodiere M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, Rozenberg F, Crow YJ, Bessis D. Stimulator of interferon genes-associated vasculopathy with onset in infancy: a mimic of childhood Granulomatosis with Polyangiitis. JAMA Dermatol. 2015; 151: 872 - 877.

73. Chia J, Eroglu FK, Ozen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, Goldbach-Mansky R, Cowen EW. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016; 74: 186 - 189.

74. J Kluk, M Rustin, PA Brogan, E Omoyinmi, DM Rowczenio, LC Willcocks, L Melly, and HJ Lachmann. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a report of a novel mutation and review of the literature. Br J Dermatol. 2014 Jan; 170(1): 215 - 217.

75. Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L, Aikawa NE, Jesus AA, Silva CA. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature - a rare case with a novel mutation. Eur J Pediatr. 2016 May; 175(5): 735-40.

76. Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis. Rev Neurol. 2018 Jan 1; 66(1): 25 - 32.

77. Fiehn C, Wolf C, Schuster M, Cura Costa E, et al. Familial chilblain lupus due to a gain-of-function mutation in STING // Ann Rheum Dis. 2017; 76(2): 468 - 472.

78. Rodero MP, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. // Ann Rheum Dis 2016; 75(12): e75-5.

79. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014 Dec; 73(12).

80. Li Y, Wilson HL, Kiss-Toth E. Regulating STING in health and disease. J Inflamm (Lond). 2017 Jun 7; 14: 11.

81. Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, Brogan PA, Rice GI, Crow YJ, Dale RC. An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation // Neurology. 2018 Feb 6; 90(6): 289 - 291.

82. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies // J Clin Invest. 2018 Jul 2; 128(7): 3041 - 3052.

83. Hoffman HM, Broderick L. JAK inhibitors in autoinflammation. J Clin Invest. 2018 Jul 2; 128(7): 2760 - 2762. doi: 10.1172/JCI121526. Epub 2018 Jun 11.

84. Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clin Pharmacol Ther. 2018 Aug; 104(2): 364 - 373. doi: 10.1002/cpt.936. Epub 2017 Dec 8.

85. Furie R, Khamashta M, Merrill JT, Werth VP et al. Investigators Anifrolumab, an Anti-Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus // Arthritis Rheumatol. 2017 Feb; 69(2): 376 - 386.

86. Khamashta M, Merrill JT, Werth VP, Furie P, et al. Sifalimumab, an monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study // Ann Rheum Dis. 2016 Nov; 75(11): 1909 - 1916.

87. Практическое руководство по детским болезням. Под ред. В.Ф. Кококлиной и А.Г. Румянцева. Иммунология детского возраста. Под ред. А.Ю. Щербины и Е.Д. Пашанова. Медпрактика-М, 2006.

88. Европейский регистр аутовоспалительных заболеваний. Электронный ресурс. Доступ: https://www.printo.it/eurofever/.

89. Н.Т. Ватутин, А.С. Смирнова, М.А. Эль-Хатиб. Семейная средиземноморская лихорадка: обзор рекомендаций EULAR, 2016. Архивъ внутренней медицины, N 6, 2016: 5 - 11.

90. Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol. 2018 Oct; 11(10): 987 - 998.